QTTB Form 4: Director awarded 53,521 options, vest by Oct 2026

Rhea-AI Filing Summary

Q32 Bio Inc. (QTTB) reported an insider equity award on a Form 4. A director received a stock option grant covering 53,521 shares on 10/23/2025, with an exercise price of $2.80 per share and an expiration date of 10/22/2035. Ownership of the derivative security is listed as Direct.

The option vests in full upon the earlier of October 23, 2026 or the date of the issuer’s next annual meeting of stockholders, subject to the director’s continued service through that date. Following the reported transaction, the director beneficially owned 53,521 derivative securities.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LAPORTE KATHLEEN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	53,521	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 53,521 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAPORTE KATHLEEN

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.8	10/23/2025		A		53,521		(1)	10/22/2035	Common Stock	53,521	$0.00	53,521	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

	/s/ Eric Bell, Attorney-in-Fact	10/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Q32 Bio (QTTB) disclose on this Form 4?

A director received a stock option grant for 53,521 shares on 10/23/2025 at an exercise price of $2.80.

What is the exercise price and size of the QTTB option grant?

The grant covers 53,521 shares with an exercise price of $2.80 per share.

When do the QTTB options vest?

They vest in full upon the earlier of October 23, 2026 or the issuer’s next annual meeting, subject to continued service.

When do the QTTB options expire?

The options expire on 10/22/2035.

What is the ownership form listed for the derivative securities?

The ownership form is Direct.

How many derivative securities are beneficially owned after the transaction?

The reporting person beneficially owned 53,521 derivative securities after the transaction.

Who filed the Form 4 for Q32 Bio (QTTB)?

It was filed by one reporting person; the filer is a Director of Q32 Bio Inc.